AR003919A1 - Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dicha - Google Patents
Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dichaInfo
- Publication number
- AR003919A1 AR003919A1 ARP960101095A AR10109596A AR003919A1 AR 003919 A1 AR003919 A1 AR 003919A1 AR P960101095 A ARP960101095 A AR P960101095A AR 10109596 A AR10109596 A AR 10109596A AR 003919 A1 AR003919 A1 AR 003919A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- accessory protein
- human
- interleukin
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Esta invención hace disponible por primera vez una proteína accesoria del receptor IL-1 humana que puede ser usado para regular los efectos de IL-1. Elagregado de esta proteina inhibe el efecto de IL-1 en las células.Por lo tanto, un aspecto de lainvención es proveer dicha proteína para el tratamiento decondiciones patológicas causadas por un exceso de actividad de las células que responden a IL-1 mediante el agregado de una cantidad de proteína accesoria delreceptor IL-1R humana (IL-1R AcP)suficiente para inhibir la activación de células por IL-1. Esta metodología también puede ser modificada, y la proteínaaccesoria puede ser usada como agente de rastreo para productos farmacéuticos. La invención comprende además el polinucleótido que codifica a dicha proteína,un vector, una célula huésped, una proteína de fusión que comprende dicha proteína, un anticuerpo que se une específicamente a dicha proteína, unacomposición farmacéutica que la comprende, un procedimiento parala preparación de dicha proteína y el empleo de dicha proteína como sustancia terapéutica parael tratamiento de respuestas inflamatorias o inmunológicas y/o para la regulación y prevención de las actividades inflamatorias o inmunológicas delainterleuquina-1, entre otras afecciones y/o enfermedades.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37626895A | 1995-01-23 | 1995-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR003919A1 true AR003919A1 (es) | 1998-09-30 |
Family
ID=23484321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960101095A AR003919A1 (es) | 1995-01-23 | 1996-01-19 | Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dicha |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0808365A1 (es) |
| JP (1) | JPH10512453A (es) |
| AR (1) | AR003919A1 (es) |
| AU (1) | AU4537096A (es) |
| BR (1) | BR9606837A (es) |
| CA (1) | CA2210724A1 (es) |
| CO (1) | CO4480033A1 (es) |
| CZ (1) | CZ208197A3 (es) |
| EA (1) | EA199700265A1 (es) |
| FI (1) | FI973089A (es) |
| HU (1) | HUP9702458A2 (es) |
| IL (1) | IL116796A0 (es) |
| MX (1) | MX9705501A (es) |
| NO (1) | NO973404D0 (es) |
| PE (1) | PE64396A1 (es) |
| PL (1) | PL321538A1 (es) |
| TR (1) | TR199700652T1 (es) |
| WO (1) | WO1996023067A1 (es) |
| ZA (1) | ZA96333B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7011696A (en) * | 1996-08-26 | 1998-03-19 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| US6974682B1 (en) | 1996-08-26 | 2005-12-13 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| DE69738948D1 (de) | 1996-12-06 | 2008-10-09 | Amgen Inc | Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| EP0979282A1 (en) * | 1997-04-30 | 2000-02-16 | F. Hoffmann-La Roche Ag | Rat st38.2 chemokine |
| US6280955B1 (en) * | 1997-12-16 | 2001-08-28 | Tularik Inc. | Interleukin-1 receptor accessory proteins, nucleic acids and methods |
| AU755391B2 (en) | 1997-12-23 | 2002-12-12 | Immunex Corporation | SIGIRR DNA and polypeptides |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| WO2002064630A2 (en) * | 2000-10-31 | 2002-08-22 | Immunex Corporation | Il-1 receptor accessory protein |
| GB2375604A (en) * | 2001-05-18 | 2002-11-20 | Warner Lambert Co | Methods for screening using interleukin soluble trimolecular complex |
| CN1547486A (zh) | 2001-06-26 | 2004-11-17 | 抗opgl抗体 | |
| KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| EP1450837A4 (en) * | 2001-08-07 | 2006-01-04 | Immunex Corp | INTERLEUKIN-1 RECEPTORS IN THE TREATMENT OF DISEASES |
| EA018072B1 (ru) | 2002-09-06 | 2013-05-30 | Амджен Инк. | Антитело к рецептору интерлейкина-1 типа 1 (il-1r1) и его применение |
| ES2694252T3 (es) | 2004-04-02 | 2018-12-19 | Swedish Orphan Biovitrum Ab (Publ) | Métodos para reducir la agregación de IL-1ra |
| PL1751175T3 (pl) * | 2004-05-05 | 2013-03-29 | Valorisation Recherche Soc En Commandite | Antagoniści receptora IL-1, kompozycje i sposoby leczenia |
| US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| WO2007004060A2 (en) * | 2005-05-05 | 2007-01-11 | Valorisation Hsj, Societe En Commandite | Cytokine receptor modulators and uses thereof |
| TW200736277A (en) | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
| WO2009120903A2 (en) * | 2008-03-26 | 2009-10-01 | Cellerant Therapeutics, Inc. | Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof |
| EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| GB2472856B (en) * | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| KR101989134B1 (ko) | 2011-01-19 | 2019-06-13 | 칸타르기아 아베 | 항―ｉｌ１ｒａｐ 항체 및 그의 인간 치료 용도 |
| CA2837651A1 (en) * | 2011-06-21 | 2012-12-27 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| WO2016183106A1 (en) | 2015-05-11 | 2016-11-17 | Natera, Inc. | Methods and compositions for determining ploidy |
| CA2990305A1 (en) | 2015-06-26 | 2016-12-29 | Mab Discovery Gmbh | Monoclonal anti-il-1racp antibodies |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| WO2018022982A1 (en) | 2016-07-29 | 2018-02-01 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| WO2018237075A1 (en) | 2017-06-20 | 2018-12-27 | The Medical College Of Wisconsin, Inc. | ASSESSING THE RISK OF GRAFT COMPLICATION WITH TOTAL ACELLULAR DNA |
| TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
| US11931674B2 (en) | 2019-04-04 | 2024-03-19 | Natera, Inc. | Materials and methods for processing blood samples |
| WO2021236962A1 (en) | 2020-05-20 | 2021-11-25 | The Medical College Of Wisconsin, Inc. | Compositions and methods for inhibiting cytokine-release syndrome |
| CN114835799A (zh) * | 2021-05-28 | 2022-08-02 | 百奥赛图江苏基因生物技术有限公司 | Il1rap基因人源化非人动物的构建方法及应用 |
-
1996
- 1996-01-15 PE PE1996000031A patent/PE64396A1/es not_active Application Discontinuation
- 1996-01-16 ZA ZA96333A patent/ZA96333B/xx unknown
- 1996-01-17 TR TR97/00652T patent/TR199700652T1/xx unknown
- 1996-01-17 IL IL11679696A patent/IL116796A0/xx unknown
- 1996-01-17 HU HU9702458A patent/HUP9702458A2/hu unknown
- 1996-01-17 MX MX9705501A patent/MX9705501A/es unknown
- 1996-01-17 WO PCT/EP1996/000181 patent/WO1996023067A1/en not_active Application Discontinuation
- 1996-01-17 BR BR9606837A patent/BR9606837A/pt unknown
- 1996-01-17 CA CA002210724A patent/CA2210724A1/en not_active Abandoned
- 1996-01-17 EA EA199700265A patent/EA199700265A1/ru unknown
- 1996-01-17 JP JP8522598A patent/JPH10512453A/ja active Pending
- 1996-01-17 CZ CZ972081A patent/CZ208197A3/cs unknown
- 1996-01-17 PL PL96321538A patent/PL321538A1/xx unknown
- 1996-01-17 AU AU45370/96A patent/AU4537096A/en not_active Abandoned
- 1996-01-17 EP EP96901291A patent/EP0808365A1/en not_active Withdrawn
- 1996-01-19 AR ARP960101095A patent/AR003919A1/es unknown
- 1996-01-22 CO CO96002329A patent/CO4480033A1/es unknown
-
1997
- 1997-07-22 FI FI973089A patent/FI973089A/fi unknown
- 1997-07-23 NO NO973404A patent/NO973404D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2210724A1 (en) | 1996-08-01 |
| TR199700652T1 (xx) | 1998-02-21 |
| FI973089A0 (fi) | 1997-07-22 |
| MX9705501A (es) | 1997-10-31 |
| CZ208197A3 (en) | 1997-11-12 |
| PE64396A1 (es) | 1997-01-28 |
| ZA96333B (en) | 1996-07-23 |
| PL321538A1 (en) | 1997-12-08 |
| EA199700265A1 (ru) | 1998-04-30 |
| WO1996023067A1 (en) | 1996-08-01 |
| HUP9702458A2 (hu) | 1998-04-28 |
| AU4537096A (en) | 1996-08-14 |
| JPH10512453A (ja) | 1998-12-02 |
| IL116796A0 (en) | 1996-05-14 |
| EP0808365A1 (en) | 1997-11-26 |
| NO973404L (no) | 1997-07-23 |
| BR9606837A (pt) | 1998-05-26 |
| CO4480033A1 (es) | 1997-07-09 |
| NO973404D0 (no) | 1997-07-23 |
| FI973089A (fi) | 1997-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR003919A1 (es) | Polinucleotido que codifica para una proteina accesoria humana para receptor de interleuquina-1, dicha proteina accesoria, un vector, una celulahuesped, un anticuerpo que se une a dicha proteina, una composicion farmaceutica que la comprende, un procedimiento para la preparacion de dicha | |
| Vitaliano et al. | The relative importance of risk factors in nonmelanoma carcinoma | |
| Rosenthal et al. | Seasonal affective disorders | |
| Boucher | The problems of vitamin d insufficiency in older people | |
| BR0213846A (pt) | métodos de induzir seletivamente a apoptose nas células alvo que expressam dr5, de inibir a proliferação de células alvo que expressam dr5 e de tratar um paciente tendo uma doença inflamatória ou doença autoimune, e, composição | |
| AR100225A2 (es) | Anticuerpos anti-factor d humanizados y usos de los mismos | |
| PT814796E (pt) | Uso de um farmaco r-aine numa composicao protectora para o tratamento do cancro colorectal | |
| SV2003001148A (es) | Derivados de benzamida tiazol y composciones farmaceuticas para inhibir la proliferacion de celulas, y metodos para su utilizacion ref. no.0097-01-sv | |
| CY1109868T1 (el) | Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c | |
| RU2010108429A (ru) | Регуляторы ммр-9 и их применение | |
| Fagan | Remembering the lessons of basic pharmacology | |
| FR2819723B1 (fr) | Composition halogene, son procede de preparation et ses utilisations | |
| ES2166770T3 (es) | Anticuerpos monoclonales contra gangliosidos y sus utilizaciones en la inmunoterapia activa especifica de tumores malignos. | |
| Kim et al. | Different patterns of emotional eating and visuospatial deficits whereas shared risk factors related with social support between anorexia nervosa and bulimia nervosa | |
| BRPI0311511A8 (pt) | "preparações farmacêuticas líquidas, e sua aplicação". | |
| Akmese et al. | Differential role of GABAergic and cholinergic ventral pallidal neurons in behavioral despair, conditioned fear memory and active coping | |
| DE69422712T2 (de) | Tris-platin-komplexe | |
| O’Connor et al. | Endurance exercise attenuates juvenile irradiation-induced skeletal muscle functional decline and mitochondrial stress | |
| Dogra et al. | Phototherapy and photochemotherapy in childhood dermatoses | |
| Orjuela‐Grimm et al. | Sunlight exposure in infancy decreases risk of sporadic retinoblastoma, extent of intraocular disease | |
| Beydoun et al. | Efficacy and tolerability of pregabalin in partial epilepsy | |
| ES2110057T3 (es) | Composicion medicinal que contiene tcf-ii. | |
| EA199901061A1 (ru) | Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии | |
| Goldstein et al. | Combined use of benserazide and carbidopa in Parkinson's disease | |
| AR023464A1 (es) | Usos novedosos de la proteina ox2 de mamifero y reactivos relacionados |